{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:30Z","timestamp":1792785870316,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000860","name":"European Society of Cardiology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000860","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Abbott Vascular Int","award":["2018\u20132021"],"award-info":[{"award-number":["2018\u20132021"]}],"id":[{"id":"https:\/\/ror.org\/05d67dc31","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Amgen Cardiovascular","award":["2016\u20132018"],"award-info":[{"award-number":["2016\u20132018"]}]},{"name":"AstraZeneca AB","award":["2017\u20132020"],"award-info":[{"award-number":["2017\u20132020"]}]},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","award":["2016\u20132018"],"award-info":[{"award-number":["2016\u20132018"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["2016\u20132019"],"award-info":[{"award-number":["2016\u20132019"]}],"id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol Myers","award":["2017\u20132019"],"award-info":[{"award-number":["2017\u20132019"]}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe GmbH","doi-asserted-by":"publisher","award":["2017\u20132020"],"award-info":[{"award-number":["2017\u20132020"]}],"id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","award":["2016\u20132019"],"award-info":[{"award-number":["2016\u20132019"]}],"id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Pharma AG","award":["2018\u20132020"],"award-info":[{"award-number":["2018\u20132020"]}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","award":["2015\u20132021"],"award-info":[{"award-number":["2015\u20132021"]}],"id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vifor","award":["2019\u20132021"],"award-info":[{"award-number":["2019\u20132021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To assess the demographic, clinical, behavioural, and treatment factors associated with health-related quality of life (HRQoL) in heart failure (HF), examine the association between HRQoL and mortality, and evaluate changes in HRQoL over 1-year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed the ESC EORP Heart Failure III Registry, including patients hospitalized with acute HF or outpatient HF visits. HRQoL was assessed using the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Generalized linear models examined associations between demographic, clinical, behavioural, and treatment characteristics with baseline HRQoL. Cox proportional hazards models assessed the relationship between baseline HRQoL and 1-year mortality. Changes in HRQoL were classified as improvement, deterioration, or mixed change across EQ-5D dimensions, and determinants of change were assessed using fixed-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 10 130 patients (acute HF: 38.6%; outpatient HF: 61.4%), those with acute HF had worse baseline HRQoL than outpatients. Older age, female sex, eGFR \u226429, NYHA class III\/IV, and dyspnoea at rest were strongly associated with lower HRQoL in both acute and outpatient HF. Lower baseline HRQoL was associated with a higher risk of death at 1 year, with a 0.1-unit decrease in HRQoL on a scale of \u22120.59 to 1.00 (equivalent to 37 days of full health lost annually) associated with a 9% higher risk of death; a finding consistent across ejection fraction categories and sex. At 1-year, 45% of patients reported improved HRQoL, and improvements were more common in those with acute HF, mildly reduced ejection fraction, and women. Use of ACEi\/ARBs\/ARNIs was associated with a modest improvement in HRQoL at 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HRQoL provides important clinical information and may provide additional insight into patients\u2019 health status and disease progression beyond conventional clinical measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejhf\/xuag236","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:38:39Z","timestamp":1790681919000},"source":"Crossref","is-referenced-by-count":0,"title":["Determinants and associations of health-related quality of life with mortality in acute and chronic heart failure: findings from the ESC HF III Registry"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4222-3205","authenticated-orcid":false,"given":"Marjan","family":"Walli-Attaei","sequence":"first","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford , Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Luengo-Fernandez","sequence":"additional","affiliation":[{"name":"National Perinatal Epidemiology Unit, Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford \u00a0","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0239-7278","authenticated-orcid":false,"given":"Alastair","family":"Gray","sequence":"additional","affiliation":[{"name":"Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Torbica","sequence":"additional","affiliation":[{"name":"Centre for Research on Health and Social Care Management (CERGAS), Bocconi University , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-4668","authenticated-orcid":false,"given":"Radu","family":"Huculeci","sequence":"additional","affiliation":[{"name":"European Heart Agency, European Society of Cardiology , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dupuytren University Hospital, and EpiMaCT Research Group, Inserm1094\/IRD270, Limoges University , Limoges ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D","family":"Timmis","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos","family":"Vardas","sequence":"additional","affiliation":[{"name":"Hygeia Hospitals Group, HHG, Athens, Greece Biomedical Research Foundation Academy of Athens (BRFAA) , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center, Heart Care Foundation , Firenze, Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-6730","authenticated-orcid":false,"given":"Jos\u00e9","family":"Leal","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford , Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026100106270782700_xuag236-B1","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/ejhf.1594","article-title":"Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis","volume":"21","author":"Jones","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026100106270782700_xuag236-B2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/eurjhf\/hft071","article-title":"Preferences of heart failure patients in daily clinical practice: quality of life or longevity?","volume":"15","author":"Kraai","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026100106270782700_xuag236-B3","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/j.jacc.2008.08.028","article-title":"Changing preferences for survival after hospitalization with advanced heart failure","volume":"52","author":"Stevenson","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026100106270782700_xuag236-B4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jchf.2019.12.011","article-title":"Endpoints in heart failure drug development: history and future","volume":"8","author":"Fiuzat","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026100106270782700_xuag236-B5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet"},{"key":"2026100106270782700_xuag236-B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ehf2.14857","article-title":"2024 update in heart failure","volume":"12","author":"Beghini","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026100106270782700_xuag236-B7","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100106270782700_xuag236-B8","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s10741-019-09890-2","article-title":"Quality of life of chronic heart failure patients: a systematic review and meta-analysis","volume":"25","author":"Moradi","year":"2020","journal-title":"Heart Fail Rev"},{"key":"2026100106270782700_xuag236-B9","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1002\/ejhf.3087","article-title":"Rationale and design of the ESC Heart Failure III Registry\u2014implementation and discovery","volume":"25","author":"Lund","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026100106270782700_xuag236-B10","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40273-019-00811-7","article-title":"Valuation of EQ-5D-5L health states in Poland: the first EQ-VT-based study in Central and Eastern Europe","volume":"37","author":"Golicki","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"2026100106270782700_xuag236-B11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/0002-8703(92)90986-6","article-title":"Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group","volume":"124","author":"Rector","year":"1992","journal-title":"Am Heart J"},{"key":"2026100106270782700_xuag236-B12","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026100106270782700_xuag236-B13","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100106270782700_xuag236-B14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"key":"2026100106270782700_xuag236-B15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hec.1608","article-title":"Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data","volume":"19","author":"Devlin","year":"2010","journal-title":"Health Econ"},{"key":"2026100106270782700_xuag236-B16","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/ejhf.2535","article-title":"Factors associated with health-related quality of life in heart failure in 23 000 patients from 40 countries","volume":"24","author":"Johansson","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026100106270782700_xuag236-B17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijcard.2018.04.102","article-title":"Patient reported outcome in HFpEF: sex-specific differences in quality of life and association with outcome","volume":"267","author":"Fax\u00e9n","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026100106270782700_xuag236-B18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s11136-022-03276-y","article-title":"Investigating gender-based differential item functioning on the Kansas City Cardiomyopathy Questionnaire (KCCQ) using qualitative content analysis","volume":"32","author":"Coles","year":"2023","journal-title":"Qual Life Res"},{"key":"2026100106270782700_xuag236-B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102217","article-title":"Changing health related quality of life and outcomes in heart failure by age, sex and subtype","volume":"64","author":"Lawson","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026100106270782700_xuag236-B20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ejhf.2154","article-title":"Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire","volume":"23","author":"Ravera","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026100106270782700_xuag236-B21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ejhf.2141","article-title":"Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis","volume":"23","author":"Turgeon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026100106270782700_xuag236-B22","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/ejhf.2738","article-title":"Health-related quality of life outcomes in PARAGON-HF","volume":"24","author":"Chandra","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag236\/71556055\/xuag236.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag236\/71556055\/xuag236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:27:14Z","timestamp":1790850434000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article\/doi\/10.1093\/ejhf\/xuag236\/8858938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag236","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"xuag236"}}